Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-910

11 evidence topics · 3 sources

Objective
Location and study date
Trial dates and status in the EU register
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using combined oral contraceptive pharmacokinetics as the study endpoint

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results

No evidence found.

Study limitations
Summary

ABX464-910 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (10 October 2023 to 31 August 2024), one site in Belgium, and 36 planned healthy women of childbearing potential aged 18 to 64 years. The doses, sampling schedule, endpoints, and the hormone measured are not public, and the summary of results is deferred until 28 February 2027. The 20-F states that the two drug-drug interaction trials were completed in 2025, whereas the register gives 31 August 2024 as the end of this trial. No pharmacokinetic or safety result has been published, so the effect of obefazimod on contraceptive exposure is unknown from public sources.